TCR Therapy Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
TCR Therapy Market is Segmented By Therapy Type (TCR-engineered T-cell Therapy, TCR-based Bispecific Antibody Therapy, TCR-based Soluble Receptor Therapy), By Target Indication (Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, Merkel Cell Cancer, Others), By Target Antigen (NY-ESO-1, EBV, gp100, Others), By End-User (Hospitals and Cancer Centers , Academic and Research Institutes, Contract Manufacturing Organizations (CMOs), Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
TCR Therapy Market Size
Market Size in USD
CAGR51.1%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 51.1% |
| Market Concentration | High |
| Major Players | Adaptimmune Therapeutics, Alaunos Therapeutics, GlaxoSmithKline, Immunocore, Intellia Therapeutics |
please let us know !
TCR Therapy Market Analysis
The TCR Therapy Market is estimated to be valued at USD 0.04 Bn in 2024 and is expected to reach USD 7.20 Bn by 2031, growing at a compound annual growth rate (CAGR) of 51.1% from 2024 to 2031. The market is poised to grow significantly over the next seven years owing to rising cancer incidences and strong pipeline of TCR cell therapies entering clinical trials for various cancer indications.
The trend in the TCR Therapy market has been positive over the past few years as technological advancements are helping researchers develop more effective TCR cell therapies. Many biopharma companies have ramped up research efforts to discover novel TCRs that can target solid tumors which has expanded the market potential. Successful clinical trial results and new regulatory approvals are positioning TCR cell therapies as an exciting area in immuno-oncology.